Target intelligence / Profile preview

Gram-negative bacterial lipopolysaccharide lipid A and anionic phospholipids (LPS Lipid A/APL)

Target
LPS Lipid A/APL
Molecular classification
Bacterial cell wall component, Glycolipid, Phospholipid
01

Overview

Gram-negative bacterial lipopolysaccharide (LPS) lipid A and anionic phospholipids are fundamental structural components of the bacterial cell envelope. Lipid A serves as the hydrophobic anchor for LPS in the outer membrane and is the primary moiety responsible for endotoxic activity, triggering severe inflammatory responses via the TLR4/MD-2 receptor complex (Park & Lee, 2013, Exp Mol Med). Anionic phospholipids, such as phosphatidylglycerol and cardiolipin, contribute to the overall negative charge and stability of both the inner and outer membranes (Epand et al., 2007, Biochim Biophys Acta). These molecules are the primary therapeutic targets for polymyxin antibiotics, which are often used as a last-resort treatment for multidrug-resistant infections. By binding to these negatively charged components, drugs like Colistin displace stabilizing divalent cations, causing membrane permeabilization and bacterial lysis (Trimble et al., 2016, Cold Spring Harb Perspect Med). Understanding these targets is critical for developing new antibiotics to combat pathogens like Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae (Poirel et al., 2017, Clin Microbiol Rev).

Other names
Lipid AEndotoxinLipopolysaccharideLPSBacterial outer membrane phospholipidsAnionic phospholipids
02

Mechanism of action

Cationic antimicrobial agents bind electrostatically to the negatively charged phosphate groups of lipid A and anionic phospholipids. This interaction displaces stabilizing divalent cations (Mg2+ and Ca2+), leading to a disorganized outer membrane, increased permeability, and the subsequent leakage of intracellular contents, resulting in bacterial cell death (Velkov et al., 2013, J Med Chem).

03

Biological functions

Structural integrityPermeability barrierImmune response inductionEndotoxic activityIon homeostasis
04

Disease associations

Gram-negative bacterial infectionSepsisSeptic shockPneumoniaUrinary tract infection
05

Safety considerations

Nephrotoxicity (acute kidney injury)Neurotoxicity (paresthesia, dizziness)Development of antimicrobial resistance (e.g., mcr-1 gene)Jarisch-Herxheimer-like reactions due to rapid endotoxin release
06

Interacting drugs

Polymyxin B

4 more in the full profile.

07

Biomarkers

Endotoxin activity assay (EAA)Procalcitonin (PCT)C-reactive protein (CRP)LPS endotoxin levels

Beyond the preview

Go deeper on Gram-negative bacterial lipopolysaccharide lipid A and anionic phospholipids (LPS Lipid A/APL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gram-negative bacterial lipopolysaccharide lipid A and anionic phospholipids (LPS Lipid A/APL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call